Scarica l'app Stockscreener
14.22
5.96%
0.80
Dopo l'orario di chiusura:
14.23
0.010
+0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Novocure Ltd Borsa (NVCR) Ultime notizie
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua - simplywall.st
[144] NovoCure Ltd SEC Filing - Stock Titan
NovoCure Ltd. Hits Day Low of $11.80 Amid Price Pressure - Markets Mojo
Vanguard Group Inc. Sells 296,555 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Shares Bought by Quantbot Technologies LP - MarketBeat
NovoCure (NVCR) CMO sells shares to cover RSU tax withholding - Stock Titan
NovoCure (NVCR) CHRO sells 1,441 shares in tax withholding trade - Stock Titan
NovoCure (NVCR) COO offloads 1,963 shares in tax sell-to-cover - Stock Titan
Tax-withholding sale of 1,029 NovoCure (NASDAQ: NVCR) shares by ex-CMO - Stock Titan
NovoCure (NVCR) CEO reports RSU vesting and tax-cover share sales - Stock Titan
Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova - Stock Titan
NovoCure (NASDAQ: NVCR) General Counsel receives 17,755-share performance award - Stock Titan
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update - Sahm
FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News
NovoCure Limited 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-03-02 - Seeking Alpha
NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment - Traders Union
Novocure gains Japan reimbursement for Optune Lua device - Investing.com Nigeria
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Novocure (NVCR) Gains Japanese Reimbursement Approval for Optune Lua - GuruFocus
Novocure (NVCR) Gains Approval for Optune Lua Reimbursement in J - GuruFocus
Novocure gains Japan reimbursement for Optune Lua device By Investing.com - Investing.com India
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer - Yahoo Finance
Equities Analysts Set Expectations for NovoCure Q1 Earnings - MarketBeat
A Look At NovoCure (NVCR) Valuation As Record 2025 Results And Optune Pax Approval Reset Growth Expectations - Yahoo Finance
NovoCure Earnings Call: Growth Builds Amid Profit Strain - TipRanks
NovoCure Shares Gap Down, Weak Start Raises Market Concerns - Markets Mojo
NovoCure Ltd. Hits Day High with 27.68% Surge in Stock Price - Markets Mojo
NovoCure Ltd. Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo
Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound - simplywall.st
NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile - simplywall.st
Hohimer Wealth Management LLC Takes Position in NovoCure Limited $NVCR - MarketBeat
Novocure to Participate in 2026 Leerink Global Healthcare Conference - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: NovoCure (NVCR) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
NovoCure (NASDAQ:NVCR) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS - MarketBeat
NovoCure (NVCR) Q4 Loss Narrowing Challenges Bearish Narrative On Persistent Unprofitability - simplywall.st
NovoCure: Q4 Earnings Snapshot - theheraldreview.com
NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
NovoCure Ltd (NVCR) Q4 2025 Earnings Call Highlights: Record Rev - GuruFocus
NovoCure Limited Q4 2025 Earnings Call Summary - Yahoo Finance
HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $49 | - GuruFocus
HC Wainwright Increases NovoCure (NASDAQ:NVCR) Price Target to $49.00 - MarketBeat
NVCR: Novocure Reports Strong Q4 Earnings and FDA Approval Boost - GuruFocus
NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
NovoCure (NASDAQ:NVCR) Shares Gap DownWhat's Next? - MarketBeat
Novocure Ltd earnings beat by $0.19, revenue topped estimates - Investing.com South Africa
NovoCure's Q4 Net Loss Narrows, Revenue Rises; 2026 Revenue Guidance Issued - marketscreener.com
Novocure reports quarterly and full year results for period ended December 31, 2025 - Traders Union
NovoCure Q4 Earnings Call Highlights - MarketBeat
NOVOCURE ($NVCR) Releases Q4 2025 Earnings - Quiver Quantitative
NovoCure: Fourth Quarter Financial Overview - Bitget
Novocure (NASDAQ: NVCR) posts 2025 results and wins FDA nod for Optune Pax - Stock Titan
FDA approves Novocure’s Optune Pax for pancreatic cancer as 2025 sales climb - Stock Titan
NovoCure (NVCR) Q4 2025 Earnings Call Transcript - The Globe and Mail
Assessing NovoCure (NVCR) Valuation After British Columbia’s Reimbursement Breakthrough for TTFields Therapy - simplywall.st
NovoCure (NASDAQ:NVCR) Shares Gap UpShould You Buy? - MarketBeat
Novocure stock jumps after Medicare billing restored - Investing.com South Africa
Novocure earnings up next: Pancreatic cancer launch in focus - Investing.com
Novocure earnings up next: Pancreatic cancer launch in focus By Investing.com - Investing.com South Africa
Novocure Ltd says CMS reinstates Medicare billing privileges retroactivelySEC filing - marketscreener.com
Novocure Ltd Says CMS Reinstates Medicare Billing Privileges RetroactivelySEC Filing - TradingView
2.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):